Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Fareeda Y. Coxon et al.|The Lancet Oncology|2017Cited by 286
2201 Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948)David Cunningham, R. Langley, Sally Stenning et al.|European Journal of Cancer|2015Cited by 31